trial

REtinal and VIsual Cortical Response in Early PSYchosis

NCTId NCT05167396
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 34 (actual)
Sponsored by Centre Psychothérapique de Nancy
Primary completion 2023-07-20
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
34 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2022-01-26
Primary completion
2023-07-20
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Retinaute (BioSerenity)EEG Headset 64 electrodes (BioSemi)MonPackOne (Metrovision)

Sponsors

Centre Psychothérapique de NancyLead Sponsor
BioSerenityCollaborator
Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator

Sites

1 total
Laxou, France

Facts & assertions

4 sourced
Enrollment
34
Phase
NA
Primary Completion Date
2023-07-20
Status
TERMINATED
relationships
The graph out of here
drug
Retinaute (BioSerenity)
drug
EEG Headset 64 electrodes (BioSemi)
drug
MonPackOne (Metrovision)
drug
lead_sponsor
Centre Psychothérapique de Nancy
company
collaborator
BioSerenity
company
Institut National de la Santé Et de la Recherche Médicale, France
company
indication
Prodromal Schizophrenia
indication
Schizotypal Personality Disorder
indication
Psychotic Disorders
indication